Organic & Biomolecular Chemistry

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about *Accepted Manuscripts* in the **Information for Authors**.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard <u>Terms & Conditions</u> and the <u>Ethical guidelines</u> still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



www.rsc.org/obc

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxx

ARTICLE TYPE

Zwitterionic Borane Adducts of N-Heterocyclic Carbenes from Mesomeric Betaines of Uracil.

Jiaxi Zhang,^a Nazar Pidlypnyi,^a Martin Nieger,^b Jan C. Namyslo,^a and Andreas Schmidt^a*

Received (in XXX, XXX) Xth XXXXXXXX 20XX, Accepted Xth XXXXXXXX 20XX 5 DOI: 10.1039/b00000x

We prepared a series of imidazolium-substituted uracilanions which are members of the class of cross-conjugated heterocyclic mesomeric betaines. They are in tautomeric equilibrium with their N-heterocyclic carbenes, uracil-6-yl-10 imidazol-3-ylidenes. These carbenes can be trapped by

- reaction with sulfur, selenium, as well as by triethylborane and triphenylborane, respectively. The latter mentioned trapping reaction yielded first representatives of a new heterocyclic zwitterionic ring system. 15 imidazo[2',1':3,4][1,4,2]diazaborolo[1,5-c]pyrimidinium-10-
- ide. Results of two single crystal X-ray structure analyses are presented.

Introduction

20

Uracil 1 is one of the four nucleobases of RNA and its derivatives display a broad variety of biological activities.¹ Due to lactim-lactam tautomerism uracil can exist in six tautomeric forms, two of which are shown in Scheme 1. Spectroscopic 25 examinations as well as calculations reveal that the diketo tautomer is the predominant form in the solid state and in solution.² The two oxygen atoms of uracil were calculated to be the most susceptible sites of attachments of complex formations³ and numerous complexes through the O4 site,⁴ or through the N3 $_{30}$ / O4⁵ and O4 / N3 / O2⁶ sites have been described. Some uracil

metal complexes through the deprotonated N1 site are known as well.⁷ To our surprise, only very few information is available concerning the interaction of uracils with boranes.⁸



Scheme 1. 40

In view of the current interest in the area of overlap between the chemistry of N-heterocyclic carbenes (NHC) and the chemistry of heterocyclic mesomeric betaines (MB)⁹ we aimed at mesomeric 45 betaines of uracil-6-yl-imidazolium betaines 2 which give rise to betaine 2 – N-heterocyclic carbene 3 tautomerism. Borane adduct

formation from N-heterocyclic carbenes is a considerably growing field of chemistry¹⁰ so that we intended to explore the behavior of our target compounds toward boranes. 50



Scheme 2.

Mesomeric betaines such as 2 are defined as neutral compounds which can exclusively be represented by dipolar resonance forms in which the positive and negative charges are delocalized within a common π -electron system. Four distinct main classes are distinguished, i) conjugated mesomeric betaines 65 (CMB), ii) ylides, iii) cross-conjugated (CCMB) mesomeric betaines, and iv) pseudo-cross-conjugated mesomeric betaines (PCCMB).11,12 The relationships to normal (NHC), abnormal (aNHC)¹³ [sometimes called mesoionic carbenes (MIC)¹⁴] and remote N-heterocyclic carbenes (rNHC)¹⁵ are summarized in 70 reviews on betaine - carbene interconversions,9 betaine and carbene chemistry of pyrazoles and indazoles,16 or complex chemistry.¹⁷

Betaine - carbene interconversions can be achieved by 75 decarboxylations, deprotonations, and tautomerisms starting from suitable betaines. Members of the class of PCCMBs^{11,12} such as imidazolium-2-carboxylates 3¹⁸ and pyrazolium-3-carboxylates¹⁹ are convenient precursors of normal N-heterocyclic carbenes such as 4 (Scheme 3). On the other hand, PCCMBs can be formed by ⁸⁰ trapping reactions of NHCs with heterocumulenes.^{9,20} Decarboxylations of CCMBs such as imidazolium-4-carboxylate 5 and pyrazolium-4-carboxylate 7 to give the aNHC 6 or the rNHC 8 require harsh conditions, and, as a consequence, only few examples of successful conversions exist.²¹ The latter 85 molecule 8 has been described as dipolar structure as shown and as cyclic bent allene, and has been studied intensively.²²



Scheme 3.

20

Deprotonations of mesomeric betaines results in the formation of anionic N-heterocyclic carbenes. Examples are the anions of the CMB imidazolium-4-olate 9,²³ the CCMB pyrimidinium-olate 10,²⁴ and the CMB sydnone $11^{9,25}$ (Scheme 4).



Scheme 4.

Tautomerism of a mesomeric betaine to an N-heterocyclic ³⁵ carbene has surprisingly been observed on examination of the mesoionic compound **12** (Busch's reagent, nitron) which is in equilibrium with **13** (Scheme 5).²⁶ Correspondingly imidazolium-4-aminide **14** is in tautomeric equilibrium with carbene **15**.²⁷



Scheme 5.

We investigated tautomeric equilibria of the ylides imidazoliumindolates **16** with their N-heterocyclic carbenes **17** (Scheme 6).

⁵⁵ We also investigated conversions into the anionic N-heterocyclic carbenes **18** and reported on borane adduct formations to **19**.²⁸



Scheme 6.

We describe here first equilibria of imidazolium-substituted ⁷⁵ uracils with their corresponding N-heterocyclic carbenes. The carbenes can be trapped with boranes to give first representatives of a new heterocyclic ring system, a zwitterionic imidazo[2',1':3,4][1,4,2]diazaborolo[1,5-c]pyrimidinium-10-ide.

Results and Discussion

⁸⁰ In continuation of our earlier work on uracils,²⁹ we reacted 6-chlorouracil **20** (6-chloropyrimidine-2,4(1*H*,3*H*)-dione) with the imidazoles **21a-e** and obtained the imidazolium salts **22a-e** in moderate to excellent yields. The anion exchange resin Amberlite IRA-400 in its hydroxy form deprotonated the salts **22a-e** to the ⁸⁵ target mesomeric betaines **2a-e** in good yields (Scheme 7).





The resonance frequency of 5-*H* of the uracil ring is diagnostic for the success of the deprotonation, as it shifts upfield by 0.15 -90 0.54 ppm in the ¹H NMR spectra, depending on the substitution pattern. The betaines **2a-e** are soluble in water and other highly polar solvents such as DMSO and methanol, but almost insoluble in acetonitrile or chloroform. In the spectra of NMR

Page 2 of 7

measurements taken in DMSO- d_6 only the betaine tautomer of **2a-e** can be seen. No traces of the N-heterocyclic carbenes **3a-e** are visible under these conditions. At least in part this can be explained by the solubility of **2a-e** which compelled us to use

- s highly polar solvents for the characterization. The betaines **2a-e** belong to the class of cross-conjugated heterocyclic mesomeric betaines (CCMB). Characteristically, the charges are restricted to separate parts of the common π -electron system in the resonance forms (I). The anionic part of the molecule is joined to the
- ¹⁰ cationic part through a union bond which starts from an unstarred position of the isoconjugated equivalent of the π -electron system which delocalizes the negative charge (**II**). This is a nodal (inactive) position of the highest occupied molecular orbital (HOMO) (**III**) which induces the charge separation in the ground state in group conjugated macmaria battaing 11/12.30

15 state in cross-conjugated mesomeric betaines.^{11,12,30}



Figure 1.

In the presence of trapping reagents, the equilibrium can be shifted toward the N-heterocyclic carbene tautomer **3a**. Thus, in ²⁵ the presence of sulfur and selenium, respectively, the thione **23** and the selenone **24** were formed in high yields (Scheme 8).



35 Scheme 8

Similarly, triethylborane in dioxane converted the betaine-NHC equilibrium into the new ring system of imidazo[2',1'][1,4,2]diazaborolo[1,5-c]pyrimidinium-10-ides

- ⁴⁰ 25a-e as fluorescent crystalline solids (Scheme 9). A similar series of reactions was performed with triphenylborane so that 2a-d were converted into 26a-d which were also obtained as crystalline compounds. Betaine 2e, however, did not react under these conditions. The resonance frequency of 5-*H* of the uracil
- ⁴⁵ moiety was detected between 5.96 ppm and 6.01 ppm (25) and between 6.20 ppm and 6.32 ppm (26), and the ¹¹B NMR signals appear between -1.6 ppm and 1.4 ppm depending on the solvent and the substitution pattern of the borane adduct, respectively. Thermogravimetric analyses show that decomposition of 25a,
- ⁵⁰ **25c**, and **25d** occurs above 270 °C in the solid state. The borane adducts proved to be stable towards acids. Thus, after treatment of **25a** with trifluoroacetic acid in methanol at reflux temperature we were able to recover the material unchanged.





Single crystals of the boron adducts 25b and 25d were obtained 65 by slow evaporation of concentrated solutions in ethanol. Results of single crystal X-ray analyses are as follows. The zwitterions 25b (Figure 2) and 25d (Figures 3 and 4) crystallized monoclinic and orthorhombic, respectively. In 25b the ethyl-hydroxy group is disordered. The B-Ccarbene bond length [B-C11; crystallographic 70 numbering] were determined to be 161.8(4) pm (25b) and 160.7(5) pm (25d), and the B-N_{uracil} bonds 162.3(3) pm and 162.8(4) pm, respectively. The corresponding bond angles N1-B1-C11 were determined to be 92.37(19)° (25b) and 92.2(3)° (25d). The three rings, uracil, diazaborole, and imidazole are 75 almost planar and dihedral angles N1-C2-N3-C4 = 1.8(5)° / $0.0(4)^{\circ}$, C11-B1-N1-C6 = $-1.0(3)^{\circ}$ / $-1.2(3)^{\circ}$ and N7-C8-C9-N10 = $-0.3(4)^{\circ}$ / $-0.2(3)^{\circ}$ were measured in **25b** and **25d**, respectively. In 25b hydrogen bonds were found between O2 and the ethylhydroxy group with N3-H and O4 of a neighbouring molecule, 80 respectively.



⁹⁰ Figure 2. Molecular structure of **25b** (minor disordered part omitted for clarity, displacement parameters are drawn at 50% probability level).



Figure 3. Molecular structure of 25d (one of the crystallographic independent molecules is shown, displacement parameters are drawn at 50% probability level).

The zwitterion 25d dimerizes through hydrogen bonds between O4 and C8-H (264 pm, 164°; crystallographic numbering).



Figure 4. Asymmetric unit of 25d showing the dimer.

35 Conclusions

15

We present first examples of cross-conjugated heterocyclic mesomeric betaines which are in tautomeric equilibrium with their N-heterocyclic carbenes. Thus imidazolium-uracilates tautomerism to uracil-6-yl-imidazol-3-ylidenes. 40 undergo Trapping reactions were performed with sulfur and selenium to

- give an imidazole-thione and -selenone, respectively. Triethylborane and triphenylborane give first representatives of a new heterocyclic zwitterionic ring system,
- ⁴⁵ imidazo[2',1':3,4][1,4,2]diazaborolo[1,5-c]pyrimidinium-10-ide. These results supplement our knowledge about the interesting area of overlap between mesomeric betaines and N-heterocyclic carbenes.
- 50 Acknowledgment. Dr. Gerald Dräger, University of Hannover (Germany) is greatfully acknowledged for measuring the high resolution mass spectra.

Experimental

General considerations. Flash-chromatography was performed with silica gel 60 (0.040-0.063 mm). Nuclear magnetic resonance (NMR)

spectra were obtained with Bruker Avance 400 and Bruker Avance III 600 MHz instruments. ¹H NMR spectra were recorded at 400 MHz or 600 MHz. ¹³C NMR spectra were recorded at 100 MHz or 150 MHz, with the $_{60}$ solvent peak or tetramethylsilane used as the internal reference. $^{11}\mathrm{B}\ \mathrm{NMR}$ spectra were recorded at 128 MHz or 192 MHz. Multiplicities are described by using the following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, and m = multiplet. FT-IR spectra were obtained on a Bruker Vektor 22 in the range of 400 to 4000 cm⁻¹. ATR-IR spectra were 65 obtained on a Bruker Alpha in the range of 400 to 4000 cm⁻¹. The mass spectra were measured with a Varian 320 MS Triple Quad GC/MS/MS with a Varian 450-GC. The electrospray ionization mass spectra (ESIMS) were measured with an Agilent LCMSD series HP 1100 with APIES. Melting points are uncorrected and were determined in an apparatus 70 according to Dr. Tottoli (Büchi). Yields are not optimized. The

compounds 22a and 2a were reported in one of our earlier publications.²

3-(2,6-Dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-1-methyl-1H-

imidazolium chloride 22a. A solution of 147 mg (1.0 mmol) of 20 and 75 164 mg (2.0 mmol) of 21a in 15 mL of chlorobenzene was heated under reflux for 8 h. After cooling, a fine, nearly white precipitate deposited, which was filtered off and thoroughly washed with diethyl ether. Recrystallization from water yielded 224 mg (98%) of a white solid. All spectroscopic data are in agreement to those reported earlier.²

3-(2,6-Dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-1-(2-hydroxyethyl)-

1H-imidazolium chloride 22b. A solution of 147 mg (1.0 mmol) of 20 and 224 mg (2.0 mmol) of 21b in 15 mL of chlorobenzene was heated under reflux for 8 h. After cooling, a fine, gray green precipitate 85 deposited, which was filtered off and thoroughly washed with diethyl ether. Recrystallization from water yielded 197 mg (76%) of gray green solid: dec > 243 °C; ¹H NMR (400 MHz, DMSO-d₆): δ = 11.54 (s, 1H), 9.95 (s, 1H), 8.03 (m, 1H), 8.22 (m, 1H), 6.15 (s, 1H), 4.33 (t, J = 5.1 Hz,

2H), 3.79 (t, J = 5.1 Hz, 2H) ppm; ¹³C NMR (100 MHz, DMSO-d₆): $\delta =$ 90 163.4, 150.7, 144.3, 136.9, 123.7, 120.6, 93.6, 58.9, 52.5 ppm; IR (ATR): 3348, 3133, 3064, 3026, 2833, 1718, 1675, 1415, 1161, 1057, 832, 583, 533 cm⁻¹; HR-ESI-MS for $C_9H_{11}N_4O_3$ required 223.0831. Found 223.0833.

95 3-(2,6-Dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-1-phenyl-1H-

imidazolium chloride 22c. A solution of 147 mg (1.0 mmol) of 20 and 288 mg (2.0 mmol) of 21c in 15 mL of chlorobenzene was heated under reflux for 8 h. After cooling, a fine, light yellow precipitate formed, which was filtered off and thoroughly washed with diethyl ether. 100 Recrystallization from water yielded 242 mg (83%) of light yellow solid:

- dec > 243 °C; ¹H NMR (400 MHz, DMSO-d₆): δ = 11.47 (s, 1H), 10.56 (s, 1H), 8.60 (m, 1H), 8.49 (m, 1H), 7.94-7.92 (m, 2H), 7.73-7.69 (m, 2H), 7.66-7.63 (m, 1H), 6.26 (s, 1H) ppm; ¹³C NMR (100 MHz, DMSO d_6): $\delta = 163.5$, 151.1, 144.8, 135.9, 134.3, 130.4, 130.2, 122.1, 121.7,
- 105 121.5, 93.1 ppm; IR (ATR): 3451, 3305, 2940, 2732, 1733, 1668, 1635, 1412, 1391, 1320, 1235, 823, 754, 685, 511, 430 cm⁻¹; HR-ESI-MS for C13H11N4O2 required 255.0882. Found 255.0884.

1-Benzyl-3-(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-1H-

- 110 imidazolium chloride 22d. A solution of 147 mg (1.0 mmol) of 20 and 316 mg (2.0 mmol) of 21d in 15 mL of chlorobenzene was heated under reflux for 8 h. After cooling, a fine, light yellow precipitate formed, which was filtered off and thoroughly washed with diethyl ether. Recrystallization from water yielded 149 mg (49%) of light yellow solid:
- ¹¹⁵ dec > 258 °C; ¹H NMR (400 MHz, DMSO-d₆): δ = 11.58 (s, 1H), 10.19 (s, 1H), 8.24 (m, 1H), 8.09 (m, 1H), 7.55-7.53 (m, 2H), 7.47-7.71 (m, 3H), 6.16 (s, 1H), 5.56 (s, 2H) ppm; 13 C NMR (100 MHz, DMSO-d₆): $\delta =$ 163.3, 150.6, 144.1, 137.0, 133.9, 128.9, 128.7, 128.2, 123.0, 121.5, 93.9, 52.6 ppm; IR (ATR): 3028, 2973, 2844, 1639, 1548, 1528, 1356, 1206,
- 120 974, 699, 438 cm⁻¹; HR-ESI-MS for C₁₄H₁₃N₄O₂ required 269.1039. Found 269.1039.

3-(2,6-Dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-1-vinyl-1Himidazolium chloride 22e. A solution of 147 mg (1.0 mmol) of 20 and

125 188 mg (2.0 mmol) of 21e in 15 mL of chlorobenzene was heated under reflux for 8 h. After cooling, a fine, light yellow precipitate formed which was filtered off and thoroughly washed with diethyl ether. Recrystallization from water yielded 135 mg (56%) of light yellow solid: dec > 194 °C; ¹H NMR (400 MHz, D₂O): δ = 9.79 (s, 1H), 8.08 (m, 1H),

8.02 (m, 1H), 7.25 (dd, J = 15.5 / 8.6 Hz, 1H), 6.11 (s, 1H), 5.98 (dd, J = 15.5 / 3.1 Hz, 1H), 5.60 (dd, J = 8.6 / 3.1 Hz, 1H) ppm; ¹³C NMR (100 MHz, D₂O): $\delta = 165.8$, 152.0, 144.5, 135.0, 127.9, 121.6, 121.2, 112.5, 95.5 ppm; IR (ATR): 3101, 3061, 2923, 2832, 1727, 1681, 1571, 1547, 1169 (1997)

 $_5$ 1160, 1096, 1041, 579, 526 cm $^{-1};$ HR-ESI-MS for $C_9H_9N_4O_2$ required 205.0726. Found 205.0726.

General procedure for the synthesis of the cross-conjugated mesomeric betaines 2a-2e.

- ¹⁰ A 150 mL portion of the anion-exchange resin Amberlite IRA-400 was filled into a column (height: 16 cm, diameter: 3 cm) and washed with 2 L of water. Then 100 mL of a 5% hydrochloric acid was added and remained in the column for 2 h. The hydrochloric acid was then rinsed out with water until pH 7 was reached. 100 mL of a 5% aqueous solution of
- ¹⁵ sodium hydroxide was added and remained in the column for 2 h. Then the base was rinsed out with water until pH = 7 was reached. Then, samples of 2 mmol of uracilylhetarenium salts **22a-22e** in 100 mL of water, respectively, were given on the resin. A flow rate of one drop per second was adjusted. The elutes were evaporated to dryness *in vacuo*.
- **6-(3-Methylimidazolio)-2,4(1***H***,3***H***)-pyrimidinedionate 2a.** 458 mg (2 mmol) of **22a** was used. The generale procedure yielded 323 mg (84%) of a white solid. All spectroscopic date are in agreement to those reported earlier.²⁹
- ²⁵ **6-(3-(2-Hydroxyethyl)-imidazolio)-2,4(1***H***,3***H***)-pyrimidinedionate 2b. 518 mg (2 mmol) of 22b** was used. The general procedure yielded 320 mg (72%) of a gray solid: dec > 230 °C; ¹H NMR (400 MHz, D₂O): δ = 8.05 (d, *J* = 2.2 Hz, 1H), 7.71 (d, *J* = 2.2 Hz, 1H), 5.97 (s, 1H), 4.45 (t, *J* 30 = 4.8, 2H), 4.01 (t, *J* = 4.8, 2H) ppm; ¹³C NMR (100 MHz, D₂O): δ =
- $_{30}$ = 4.8, 2H), 4.01 (t, *J* = 4.8, 2H) ppm; 13 C NMR (100 MHz, D₂O): δ = 169.5, 160.5, 156.0, 132.4, 119.5, 87.0, 59.6, 52.3 ppm; IR (ATR): 3381, 3079, 3044, 2955, 1608, 1535, 1476, 1439, 1373, 1101, 1071, 788, 585, 546 cm⁻¹; HR-ESI-MS for C₉H₁₁N₄O₃ required 223.0831. Found 223.0831.
- ³⁵
 6-(3-Phenylimidazolio)-2,4(1*H*,3*H*)-pyrimidinedionate 2c. 582 mg (2 mmol) of 22c was used. The general procedure yielded 406 mg (80%) of a light yellow solid: dec > 267 °C; ¹H NMR (400 MHz, DMSO-d₆): δ = 10.28 (s, 1H), 10.20 (s, 1H), 8.48 (m, 1H), 8.46 (m, 1H), 7.92-7.90 (m,
- $_{40}$ 2H), 7.69-7.65 (m, 2H), 7.63-7.59 (m, 1H), 5.90 (s, 1H) ppm; ^{13}C NMR (100 MHz, DMSO-d_6): δ = 166.2, 157.1, 152.7, 134.6, 133.9, 130.0, 122.2, 121.8, 119.9, 85.5 ppm; IR (ATR): 3394, 3116, 3050, 2970, 1726, 1676, 1618, 1545, 1217, 1109, 1081, 972, 764, 601, 528, 421 cm^{-1}; HR-ESI-MS for $C_{13}H_{11}N_4O_2$ required 255.0882. Found 255.0884.
- **6-(3-Benzylimidazolio)-2,4(1***H***,3***H***)-pyrimidinedionate 2d. 610 mg (2 mmol) of 22d was used. The general procedure yielded 413 mg (77%) of a light yellow solid: dec > 278 °C; ¹H NMR (400 MHz, DMSO-d₆): \delta = 9.97 (s, 1H), 9.74 (s, 1H), 8.28 (m, 1H), 7.88 (m, 1H), 7.49-7.47 (m, 2H),**
- 50 7.44-7.41 (m, 2H), 7.40-7.38 (m, 1H), 5.62 (s, 1H), 5.45 (s, 2H) ppm; $^{13}\mathrm{C}$ NMR (100 MHz, DMSO-d_6): δ = 167.4, 159.0, 155.3, 135.1, 129.5, 129.3, 128.9, 123.5, 119.7, 83.3, 52.8 ppm; IR (ATR): 3152, 3061, 2948, 2775, 1610, 1544, 1475, 1395, 1376, 1185, 1110, 908, 851, 768, 716, 701, 543, 447 cm^{-1}; HR-ESI-MS for $C_{14}H_{13}N_4O_2$ required 269.1039. Found 55 269.1039.

6-(3-Vinylimidazolio)-2,4(1*H***,3***H***)-pyrimidinedionate 2e. 482 mg (2 mmol) of 22e was used. The general procedure yielded 318 mg (78%) of a light yellow solid: dec > 226 °C; ¹H NMR (400 MHz, D₂O): δ = 8.08 (d, 60** *J* **= 2.3 Hz, 1H), 7.94 (d,** *J* **= 2.3 Hz, 1H), 7.23 (dd,** *J* **= 15.5 / 8.6 Hz, 1H), 5.96 (s, 1H), 5.95 (dd,** *J* **= 15.5 / 3.0 Hz, 1H), 5.56 (dd,** *J* **= 8.6 / 3.0 Hz, 1H) pm; ¹³C NMR (100 MHz, D₂O): δ = 169.4, 160.5, 155.8, 128.1, 140.0 HI + 100.0 Hz +**

120.2, 119.8, 111.1, 87.0 ppm; IR (ATR): 3372, 3110, 2966, 1676, 1623, 1490, 1085, 975, 781, 612, 448 cm⁻¹; HR-ESI-MS for $C_9H_9N_4O_2$ required 65 205.0726. Found 205.0727.

6-(3-Methyl-2-thioxo-2,3-dihydro-1*H*-imidazol-1-yl)pyrimidine-

2,4(1*H***,3***H***)-dione 23.** 326 mg (1 mmol) of caesium carbonate was added to a suspension of 96 mg (0.5 mmol) of **22a** and 38 mg (0.6 mmol) of ⁷⁰ sulfur in 15 mL of dry acetonitrile. The mixture was heated under a nitrogen atmosphere under reflux for 7 h. After cooling, the solvent was evaporated *in vacuo*. The product was separated with a column chromatography (pure ethyl acetate). Evaporating to dryness *in vacuo*

formed a light yellow solid: yield 82 mg (73%); dec > 320 °C; ¹H NMR 75 (400 MHz, DMSO-d₆): δ = 9.77 (s, 1H), 7.62 (d, *J* = 2.6 Hz, 1H), 7.22 (d, *J* = 2.6 Hz, 1H), 6.78 (s, 1H), 3.48 (s, 3H) ppm; ¹³C NMR (100 MHz, DMSO-d₆): δ = 167.0, 160.9, 158.7, 157.0, 118.4, 115.5, 88.0, 34.4 ppm; IR (ATR): 3114, 2915, 2812, 1683, 1617, 1564, 1399, 1366, 1268, 1233, 811, 541, 531, 431 cm⁻¹; HR-ESI-MS for C₈H₇N₄O₂S required 223.0290. 80 Found 223.0285.

6-(3-Methyl-2-selenoxo-2,3-dihydro-1*H*-imidazol-1-yl)pyrimidine-

2,4(1*H***,3***H***)-dione 24.** 326 mg (1 mmol) of caesium carbonate was added to a suspension of 96 mg (0.5 mmol) of **22a** and 47 mg (0.6 mmol) of selenium in 15 mL of dry acetonitrile. The mixture was heated under a nitrogen atmosphere under reflux for 7 h. After cooling, the solvent was evaporated *in vacuo*. The product was separated with a column chromatography (pure ethyl acetate). Evaporating to dryness *in vacuo* formed a yellow solid: yield 125 mg (92%); dec > 312 °C; ¹H NMR (400 90 MHz, DMSO-d₆): δ = 9.80 (s, 1H), 7.69 (d, *J* = 2.4 Hz, 1H), 7.41 (d, *J* = 2.4 Hz, 1H), 6.58 (s, 1H), 3.58 (s, 3H) ppm; ¹³C NMR (100 MHz, DMSO-d₆): δ = 166.7, 158.4, 157.2, 153.7, 120.5, 118.4, 89.6, 36.5 ppm; IR (ATR): 3115, 2916, 1612, 1563, 1486, 1446, 1365, 1227, 862, 783, 459 cm⁻¹; HR-ESI-MS for C₈H₇N₄O₂Se required 270.9734. Found 270.9736.

10,10-Diethyl-1-methyl-6,8-dioxo-6,7,8,10-tetrahydro-1*H*-

imidazo[2',1':3,4][1,4,2]diazaborolo[1,5-c]pyrimidinium-10-ide 25a. A solution of 460 mg (5 mmol) of BEt₃ in 2 mL of dioxane was added to a suspension of 96 mg (0.5 mmol) of **2a** in 5 mL of dioxane. The mixture ¹⁰⁰ was then stirred at 200 °C under a nitrogen atmosphere in a Schlenk-tube for 24 h. After cooling, the solvent was evaporated *in vacuo*. The product was separated by column chromatography (ethyl acetate : ethanol = 2 : 1). After evaporating to dryness *in vacuo*, recrystallization from ethanol formed a colorless solid: yield 61 mg (47%); dec > 251 °C; ¹H NMR (400 ¹⁰⁵ MHz, CD₃OD): δ = 8.00 (d, *J* = 2.0 Hz, 1H), 7.56 (d, *J* = 2.0 Hz, 1H), 5.96 (s, 1H), 3.89 (s, 1H), 1.07-0.98 (m, 2H), 0.74-0.65 (m, 2H), 0.51 (t, *J* = 7.7 Hz, 6H) ppm; ¹³C NMR (100 MHz, D₂O): δ = 168.5, 153.8, 153.5, 128.4, 115.2, 83.4, 35.8, 12.4, 10.9 ppm; ¹¹B NMR (192 MHz, CD₃CN): δ = 1.3 ppm; IR (ATR): 3118, 2942, 2864, 1704, 1634, 1482, 1398, 1317, ¹¹⁰ 796, 769, 599, 451 cm⁻¹; HR-ESI-MS for C₁₂H₁₈N₄O₂B required 261.1523. Found 261.1525.

10,10-Diethyl-1-(hydroxymethyl)-6,8-dioxo-6,7,8,10-tetrahydro-1H-

115 imidazo[2',1':3,4][1,4,2]diazaborolo[1,5-c]pyrimidinium-10-ide 25b. A solution of 460 mg (5 mmol) of BEt₃ in 2 mL of dioxane was added to a suspension of 111 mg (0.5 mmol) of 2b in 5 mL of dioxane. The mixture was stirred at 200 °C under a nitrogen atmosphere in a Schlenktube for 24 h. After cooling, the solvent was evaporated in vacuo. The 120 product was separated by column chromatography (ethyl acetate : ethanol = 2 : 1). After evaporating to dryness in vacuo, recrystallization from ethanol formed a colorless solid: yield 30 mg (16%); dec > 185 °C; $^1\mathrm{H}$ NMR (400 MHz, DMSO-d₆): δ = 10.60 (s, 1H), 8.22 (d, J = 2.0 Hz, 1H), 7.77 (d, J = 2.0 Hz, 1H), 6.00 (s, 1H), 4.12 (t, J = 5.3 Hz, 2H), 3.75 (t, J =125 5.3 Hz, 2H), 0.92-0.83 (m, 2H), 0.54-0.45 (m, 2H), 0.40 (t, J = 7.6 Hz, 6H) ppm; ¹³C NMR (100 MHz, DMSO-d₆): $\delta = 165.0$, 151.2, 150.7, 136.0, 129.9, 129.8, 127.0, 123.7, 115.0, 82.5, 12.0, 10.4 ppm; ¹¹B NMR $(192 \text{ MHz}, \text{CD}_3\text{CN})$: $\delta = -0.4 \text{ ppm}$; IR (ATR): 3386, 3158, 3136, 3022, 2935, 2900, 2659, 1668, 1641, 1563, 1452, 1402, 1079, 787, 724, 595, 130 446 cm⁻¹; HR-ESI-MS for C₁₃H₁₉N₄O₃BNa required 313.1448. Found 313.1448.

10,10-Diethyl-6,8-dioxo-1-phenyl-6,7,8,10-tetrahydro-1*H*imidazo[2',1':3,4][1,4,2]diazaborolo[1,5-c]pyrimidinium-10-ide 25c. A

¹³⁵ solution of 460 mg (5 mmol) of BEt₃ in 2 mL of dioxane was added to a suspension of 127 mg (0.5 mmol) of 2c in 5 mL of dioxane. The mixture was stirred at 200 °C under a nitrogen atmosphere in a Schlenk-tube for 24 h. After cooling, the solvent was evaporated *in vacuo*. The product was separated by column chromatography (ethyl acetate : ethanol = 2 : 1).
¹⁴⁰ After evaporating to dryness *in vacuo*, recrystallization from ethanol formed a yellow solid: yield 40 mg (25%); dec > 204 °C; ¹H NMR (400 MHz, DMSO-d₆): δ = 10.70 (s, 1H), 8.49 (d, *J* = 2.1 Hz, 1H), 8.20 (d, *J* = 2.1 Hz, 1H), 7.69-7.64 (m, 2H), 7.62-7.58 (m, 3H), 6.13 (s, 1H), 0.91-0.82 (m, 2H), 0.37 (t, *J* = 7.5 Hz, 6H), 0.33-0.24 (m, 2H) pm; ¹³C NMR ¹⁴⁵ (100 MHz, DMSO-d₆): δ = 165.2, 151.3, 151.0, 126.7, 114.0, 81.9, 59.6, 50.8, 11.7, 10.5 ppm; ¹¹B NMR (128 MHz, DMSO-d₆): δ = 0.0 ppm; IR

(ATR): 3135, 2917, 2858, 1694, 1637, 1593, 1471, 1451, 1395, 1258, 793, 763, 750, 735, 690 cm $^{-1}$; HR-ESI-MS for $C_{17}H_{19}N_4O_2BNa$ required 345.1499. Found 345.1500.

- 5 1-Benzyl-10,10-diethyl-6,8-dioxo-6,7,8,10-tetrahydro-1*H*imidazo[2',1':3,4][1,4,2]diazaborolo[1,5-c]pyrimidinium-10-ide 25d. A solution of 460 mg (5 mmol) of BEt₃ in 2 mL of dioxane was added to a suspension of 134 mg (0.5 mmol) of 2d in 5 mL of dioxane. The
- mixture was stirred at 200 °C under a nitrogen atmosphere in a Schlenktube for 24 h. After cooling, the solvent was evaporated *in vacuo*. The product was separated by column chromatography (ethyl acetate : ethanol = 2 : 1). After evaporating to dryness *in vacuo*, recrystallization from ethanol formed a yellow solid: yield 56 mg (33%); dec > 262 °C; ¹H NMR (400 MHz, DMSO-d₆): $\delta = 10.62$ (s, 1H), 8.27 (d, J = 1.4 Hz, 1H), 7.81 (d, L = 1.4 Hz, 1H), (d, L = 1.4 Hz, 2H), 7.81 (d, L = 1.4 Hz, 1H), (d, L = 1.4 Hz, 2H),
- ¹⁵ 7.81 (d, *J* = 1.4 Hz, 1H), 7.43-7.40 (m, 2H), 7.38-7.35 (m, 1H), 7.32-7.31 (m, 2H), 6.01 (s, 1H), 5.34 (s, 2H), 0.89-0.83 (m, 2H), 0.50-0.43 (m, 2H), 0.33 (t, *J* = 5.1 Hz, 6H) ppm; ¹³C NMR (100 MHz, DMSO-d₆): δ = 165.6, 151.8, 151.4, 135.6, 129.3, 128.9, 128.1, 127.0, 115.3, 82.6, 52.1, 12.1, 10.9 ppm; ¹¹B NMR (192 MHz, CD₃CN): δ = -0.2 ppm; IR (ATR): 3173,
- $_{20}$ 2928, 2896, 2855, 2814, 1706, 1661, 1560, 1475, 1367, 1238, 794, 758, 706, 694, 446, 419 cm $^{-1};$ HR-ESI-MS for $C_{18}H_{21}N_4O_2BNa$ required 359.1655. Found 359.1658.

1-Methyl-6,8-dioxo-10,10-diphenyl-6,7,8,10-tetrahydro-1H-

- ²⁵ imidazo[2',1':3,4][1,4,2]diazaborolo[1,5-c]pyrimidinium-10-ide 26a. A solution of 242 mg (1 mmol) of BPh₃ in 2 mL of dichloromethane was added to a suspension of 96 mg (0.5 mmol) of 2a in 5 mL of dioxane. The mixture was stirred at 200 °C under a nitrogen atmosphere in a Schlenktube for 24 h. After cooling, the solvent was evaporated *in vacuo*. The
- ³⁰ product was separated by column chromatography (ethyl acetate : ethanol = 2 : 1). After evaporating to dryness *in vacuo*, recrystallization from ethanol formed a white solid: yield 91 mg (51%); dec > 352 °C; ¹H NMR (400 MHz, DMSO-d₆): δ = 10.73 (s, 1H), 8.32 (d, *J* = 2.0 Hz, 1H), 7.76 (d, *J* = 2.0 Hz, 1H), 7.23-7.12 (m, 10H), 6.20 (s, 1H), 3.29 (s, 3H) ppm;
- 33 ^{13}C NMR (100 MHz, DMSO-d_6): δ = 164.9, 150.9, 150.3, 144.3, 133.5, 128.0, 127.1, 126.0, 114.6, 83.4, 35.4 ppm; ^{11}B NMR (192 MHz, CD_3CN): δ = -1.3 ppm; IR (ATR): 3154, 3115, 3041, 1683, 1661, 1460, 1398, 1240, 989, 876, 714, 700, 592, 582, 435 cm^{-1}. HR-ESI-MS for $C_{20}H_{17}N_4O_2BNa$ required 379.1342. Found 379.1343.
- **1-(2-Hydroxyethyl)-6,8-dioxo-10,10-diphenyl-6,7,8,10-tetrahydro-1***H***imidazo[2',1':3,4][1,4,2]diazaborolo[1,5-c]pyrimidinium-10-ide** 26b. A solution of 242 mg (1 mmol) of BPh₃ in 2 mL of dichloromethane was added to a suspension of 111 mg (0.5 mmol) of 2b in 5 mL of dioxane.
- ⁴⁵ The mixture was stirred at 200 °C under a nitrogen atmosphere in a Schlenk-tube for 24 h. After cooling, the solvent was evaporated *in vacuo*. The product was separated with a column chromatography (ethyl acetate : ethanol = 2 : 1). After evaporating to dryness *in vacuo*, recrystallization from ethanol formed a light brown solid: yield 37 mg
- ⁵⁰ (19%); dec > 255 °C; ¹H NMR (400 MHz, DMSO-d₆): δ = 10.71 (s, 1H), 8.34 (d, J = 2.0 Hz, 1H), 7.74 (d, J = 2.0 Hz, 1H), 7.23-7.15 (m, 10H), 6.21 (s, 1H), 5.01 (t, J = 5.0 Hz, 1H), 3.95 (t, J = 5.0 Hz, 2H), 3.23 (q, J = 5.0 Hz, 2H) ppm; ¹³C NMR (100 MHz, DMSO-d₆): δ = 164.9, 150.7, 150.3, 144.3, 133.5, 127.7, 127.1, 126.0, 114.3, 83.4, 58.8, 50.8 ppm; ¹¹B
- ⁵⁵ NMR (128 MHz, DMSO-d₆): δ = -1.2 ppm; IR (ATR): 3156, 3091, 3004, 1699, 1645, 1478, 1079, 996, 810, 752, 717, 701, 590, 433 cm⁻¹; HR-ESI-MS for C₂₁H₁₉N₄O₃BNa required 409.1448. Found 409.1447.

6,8-Dioxo-1,10,10-triphenyl-6,7,8,10-tetrahydro-1*H*-

- ⁶⁰ imidazo[2',1':3,4][1,4,2]diazaborolo[1,5-c]pyrimidinium-10-ide 26c. A solution of 242 mg (1 mmol) of BPh₃ in 2 mL of dichloromethane was added to a suspension of 127 mg (0.5 mmol) of 2c in 5 mL of dioxane. The mixture was stirred at 200 °C under a nitrogen atmosphere in a Schlenk-tube for 24 h. After cooling, the solvent was evaporated *in*
- ⁶⁵ *vacuo*. The product was separated by column chromatography (ethyl acetate : ethanol = 2 : 1). After evaporating to dryness *in vacuo*, recrystallization from ethanol formed a light yellow solid: yield 65 mg (31%); dec > 339 °C; ¹H NMR (400 MHz, DMSO-d₆): δ = 10.79 (s, 1H), 8.62 (d, *J* = 2.0 Hz, 1H), 8.22 (d, *J* = 2.0 Hz, 1H), 7.47-7.42 (m, 1H),
- 70 7.36-7.32 (m, 2H), 7.20-7.17 (m, 2H), 7.10 (s, 10H), 6.32 (s, 1H) ppm; 13 C NMR (100 MHz, DMSO-d_6): δ = 164.9, 150.7, 150.0, 144.4, 135.7, 133.5, 129.7, 129.4, 127.4, 126.9, 125.9, 123.9, 115.5, 83.9 ppm; 11 B NMR (128 MHz, DMSO-d_6): δ = -1.0 ppm; IR (ATR): 3161, 3135, 2999,

2823, 1711, 1662, 1480, 1428, 1392, 1251, 804, 762, 720, 689, 598, 546, 75 443 $\rm cm^{-1};~HR\text{-}ESI\text{-}MS$ for $\rm C_{25}H_{19}N_4O_2BNa$ required 441.1499. Found 441.1501.

1-Benzyl-6,8-dioxo-10,10-diphenyl-6,7,8,10-tetrahydro-1*H*imidazo[2',1':3,4][1,4,2]diazaborolo[1,5-c]pyrimidinium-10-ide 26d.

- ⁸⁰ A solution of 242 mg (1 mmol) of BPh₃ in 2 mL of dichloromethane was added to a suspension of 134 mg (0.5 mmol) of 2d in 5 mL of dioxane. The mixture was stirred at 200 °C under a nitrogen atmosphere in a Schlenk-tube for 24 h. After cooling, the solvent was evaporated *in vacuo*. The product was separated by column chromatography (ethyl
- ⁸⁵ acetate : ethanol = 2 : 1). After evaporating to dryness *in vacuo*, recrystallization from ethanol formed a light yellow solid: yield 90 mg (42%); dec > 346 °C; ¹H NMR (400 MHz, DMSO-d₆): δ = 10.75 (s, 1H), 8.36 (d, *J* = 2.1 Hz, 1H), 7.68 (d, *J* = 2.1 Hz, 1H), 7.30-7.27 (m, 4H), 7.22-7.17 (m, 7H), 7.14-7.10 (m, 2H), 6.64-6.61 (m, 2H), 6.20 (s, 1H),
- ⁹⁰ 5.11 (s, 2H) ppm; ¹³C NMR (100 MHz, DMSO-d₆): δ = 164.9, 150.8, 150.2, 144.4, 134.0, 133.5, 128.5, 128.4, 128.1, 127.3, 126.2, 126.1, 115.6, 83.6, 51.6 ppm; ¹¹B NMR (128 MHz, DMSO-d₆): δ = -1.5 ppm; IR (ATR): 3169, 3148, 3024, 3002, 1712, 1662, 1567, 1472, 1363, 1339, 993, 807, 752, 707, 588, 570, 433 cm⁻¹. HR-ESI-MS for C₂₆H₂₁N₄O₂BNa ⁹⁵ required 455.1655. Found 455.1652.

Notes and references

 ^a Clausthal University of Technology, Institute of Organic Chemistry, Leibnizstrasse 6, D-38678 Clausthal-Zellerfeld, Germany. Fax: +49-5323-722858; Tel:49-5323-723861; E-mail: schmidt@ioc.tu-clausthal.de
 ^b Laboratory of Inorganic Chemistry, Department of Chemistry, University of Helsinki, P.O. Box 55 (A.I. Virtasen aukio 1), FIN-00014
 ¹⁰⁵ University of Helsinki, Finland.

[†] Electronic Supplementary Information (ESI) available: Data of the single crystal X-ray analyses as well as the cif-files (CCDC-976125 (**25b**) and CCDC-976126 (**25d**). NMR spectra. See DOI: XXXXXXXXXXXX

- M. S. Novikov, A. N. Geisman, *Chem. Heterocycl. Comp.* 2014, **49**, 1426; S. A. Grabovskiy, Y. I. Murinov, N. N. Kabal'nova, *Curr. Org. Chem.* 2012, **16**, 2389; A. O. Dolinkin, M. S. Chernov'yants, *Pharm. Chem. J.* 2010, **44**, 99; D. Lecca, S. Ceruti, *Biochem. Pharmacol.* 2008, **75**, 1869.
 - 2. M. Goodgame, D. A. Jakubovic, Coord. Chem. Rev. 1987, 79, 97.
 - 3. R. Parajuli, Int. J. Chem. Sci. 2012, 10, 1477.
- W. Zhu, X. Luo, C. M. Puah, X. Tan, J. Shen, J. Gu, K. Chen, H. Jiang, *J. Phys. Chem. A* 2004, **108**, 4008; M. Goodgame, K.W. Johns, *J. Chem. Soc., Dalton Trans.* 2 **1977**, 1680; J. A. Carrabine, M. Sundaralingham, *Biochemistry* 1971, **10**, 292.
- B. Lippert, W. Micklitz, O. Renn, G. Trötscher, I. Dieter, G. Frommer, *Pure Appl. Chem.* 1990, **62**, 1075; B. Lippert, *Inorg. Chim. Acta* 1981, **55**, 5.
- 125 6. T. Matsubara, K. Hirao, J. Molec. Struct. (Theochem) 2002, 581, 203.
 - K. K. Narang, V. P. Singh, D. Bhattacharya, *Transition Met. Chem.* 1997, 22, 333; Md. Abdus Salam, H. Q. Yuan, T. Kikuchi, N. Anand Prasad, I. Fujisawa, K. Aoki, *Inorg. Chim. Acta* 2009, 362, 1158.
 - M. E. Kletskii, E. B. Tsupak, D. A. Nazarov, *Chem. Heterocycl. Comp.* 2002, **38**, 965.
 - 9. A. Schmidt, S. Wiechmann, T. Freese, ARKIVOC 2013, i, 424.
 - D. P. Curran, A. Solovyev, M. M. Brahmi, L. Fensterbank, M. Malacria, E. Lacôte, E. Angew. Chem. Int. Ed. Engl. 2011, 50, 10294.
- ¹³⁵ 11. W. D. Ollis, S. P. Stanforth, C. A. Ramsden, *Tetrahedron* 1985, **41**, 2239.
 - A. Schmidt, Curr. Org. Chem. 2004, 8, 653; A. Schmidt, Adv. Heterocycl. Chem. 2003, 85, 67. H. Wamhoff, A. Schmidt, J. Org. Chem. 1993, 58, 6976.
- 140 13. S. Grundemann, A. Kovacevic, M. Albrecht, J. W. Faller, R. H. Crabtree, *Chem. Commun.* 2001, 2274.
 - 14. G. Guisado-Barrios, J. Bouffard, B. Donnadieu, G. Bertrand, *Angew. Chem.* 2010, **122**, 4869; *Angew. Chem. Int. Ed.* 2010, **49**, 4759.

- O. Schuster, L. Yang, H. G. Raubenheimer, M. Albrecht, *Chem. Rev.* 2009, **109**, 3445; H. G. Raubenheimer, S. Cronje, *Dalton Trans.* 2008, 1265; C. E. Strasser, E. Stander-Grobler, O. Schuster, S. Cronje, H. G. Raubenheimer, *Eur. J. Inorg. Chem.* 2009, 1905.
- ⁵ 16. A. Schmidt, Z. Guan, Z. Synthesis 2012, 3251; A. Schmidt, A. Dreger, Curr. Org. Chem. 2011, **15**, 2897; A. Schmidt, A. Dreger, Curr. Org. Chem. 2011, **15**, 1423; A. Schmidt, A. Beutler, B. Snovydovych, Eur. J. Org. Chem. **2008**, 4073.
- 17. R. H. Crabtree, Coord. Chem. Rev. 2013, 257, 755
- 10 18. B. R. van Ausdall, B. R. J. L. Glass, K. M. Wiggins, A. M. Aarif, J. Louie, *J. Org. Chem.* 2009, **74**, 7935; H. Zhou, W.-Z. Zhang, C.-H. Liu, J.-P. Qu, X.-B. Lu, *J. Org. Chem.* 2008, **73**, 8039; A. M. Magill, K. G. Cavell, B. F. Yates, *J. Am. Chem. Soc.* 2004, **126**, 8717; M. Fèvre, J. Pinaud, A. Leteneur, Y. Gnanou, J. Vignolle, D. Taton, K.
- Miqueu, J.-M. Sotiropoulos, J. Am. Chem. Soc. 2012, 134, 6776; J. Li, J. Peng, G. Zhang, Y. Bai, G. Lai, X. Li, New J. Chem. 2010, 34, 1330; T. Le Gall, S. Baltatu, S. K. Collins, Synthesis 2011, 3687; T. K. Olszewski, D. E. Jaskólska, Heteroatom Chem. 2012, 23, 605; W. Wyer, G. Gucciardo, V. Leigh, H. Müller-Bunz, M. Albrecht, J. Organomet. Chem. 2011, 696, 2882.
- A. Schmidt, T. Habeck, *Lett. Org. Chem.* 2005, 2, 37; A. Schmidt, T. Habeck, L. Merkel, M. Mäkinen, P. Vainiotalo, *Rapid Comm. Mass Spectrom.* 2005, 19, 2211; A. Schmidt, N. Münster, A. Dreger, *Angew. Chem.* 2010, 122, 2851; *Angew. Chem. Int. Ed.* 2010, 49,
- 25 2790; A. Dreger, R. Cisneros Camuña, N. Münster, T. A. Rokob, I. Pápai, A. Schmidt, *Eur. J. Org. Chem.* **2010**, 4296.
- L. Delaude, *Eur. J. Inorg. Chem.* 2009, 1681; S.-i. Matsuoka, Y. Tochigi, K. Takagi, M. Suzuki, *Tetrahedron* 2012, 68, 9836; L. M. Yagupol'skii, Yu. P. Kokhanovskii, K. I. Petko, *Russ. J. Org. Chem.*
- 2010, 46, 903; M. Hans, Q. Willem, J. Wouters, A. Demonceau, L. Delaude, *Organometallics* 2011, 30, 6133; Z. Guo, N. R. Song, J. H. Moon, M. Kim, E. J. Jun, J. Choi, J. Y. Lee, C. W. Bielawski, J. L. Sessler, J. Yoon, *J. Am. Chem. Soc.* 2012, 134, 17846.
- A. Dreger, M. Nieger, M. H. H. Drafz, A. Schmidt, Z. Naturforsch.
 2012, 67b, 359; A. Schmidt, A. Beutler, M. Albrecht, F. J. Ramírez, Org. Biomol. Chem. 2008, 6, 287.
- V. Lavallo, C. A. Dyker, B. Donnadieu, G. Bertrand, Angew. Chem. 2008, **120**, 5491; Angew. Chem. Int. Ed. 2008, **47**, 5411; V. Lavallo, C. A. Dyker, B. Donnadieu, G. Bertrand, Angew. Chem. 2009, **121**,
- ⁴⁰ 1568; Angew. Chem. Int. Ed. 2009, **48**, 1540; M. Christl, B. Engels, Angew. Chem. 2009, **121**, 1566; Angew. Chem. Int. Ed. 2009, **48**, 1538; Y. Han, H. V. Huynh, Dalton Trans 2011, **40**, 2141; M. M. Hänninen, A. Peuronen, H. M. Tuononen, Chem. Eur. J. 2009, **15**, 7287.
- ⁴⁵ 23. L. Benhamou, N. Vujkovic, V. César, H. Gornitzka, N. Lugan, G. Lavigne, *Organometallics* 2010, **29**, 2616; L. Benhamou, V. César, H. Gornitzka, N. Lugan, G. Lavigne, *Chem. Commun.* 2009, 4720; A. T. Biju, K. Hirano, R. Fröhlich, F. Glorius, *Chem. Asian J.* 2009, **4**, 1786.
- 50 24. G. Lavigne, V. César, N. Lugan, *Chem. Eur. J.* 2010, 16, 11432; V. César, N. Lugan, G. Lavigne, *J. Am. Chem. Soc.* 2008, 130, 11286.
 25. S. Wiechmann, T. Freese, manuscript in preparation.
 - C. Färber, M. Leibold, C. Bruhn, M. Maurer, U. Siemeling, *Chem. Commun.* 2012, 48, 227.
- 55 27. V. César, J.-C. Tourneux, N. Vujkovic, R. Brousses, N. Lugan, G. Lavigne, *Chem. Commun.* 2012, **48**, 2349; A. A. Danopoulos, K. Yu. Monakhov, P. Braunstein, *Chem. Eur. J.* 2013, **19**, 450.
 - N. Pidlypnyi, J. C. Namyslo, M. H. H. Drafz, M. Nieger, A. Schmidt, J. Org. Chem. 2013, 78, 1070; N. Pidlypnyi, F. Uhrner, M. Nieger,
- 60 M. H. H. Drafz, E. G. Hübner, J. C. Namyslo, A. Schmidt, *Eur. J. Org. Chem.* 2013, 7739.
 - A. Schmidt, M. K. Kindermann, P. Vainiotalo, M. Nieger, J. Org. Chem. 1999, 64, 9499.
 - 30. K. T. Potts, P. M. Murphy, W. R. Kuehnling, J. Org. Chem. 1988, 53,
- 65 2889; K. T. Potts, P. M. Murphy, M. R. DeLuca, W. R. Kuehnling, J. Org. Chem. 1988, 53, 2898.